Status:
COMPLETED
Evaluation of Toric Soft Contact Lenses Containing a Chromophore to Block High-Energy Visible Light
Lead Sponsor:
Johnson & Johnson Vision Care, Inc.
Conditions:
Visual Acuity
Eligibility:
All Genders
18-39 years
Phase:
NA
Brief Summary
This will be a 4-visit, randomized, controlled, single-masked, bilateral wear, dispensing, 2-treament, 2-sequence, 3-period crossover study to evalulate overall vision and comfort..
Eligibility Criteria
Inclusion
- Potential subjects must satisfy of all the following criteria to be enrolled in the study.
- Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
- Appear able and willing to adhere to the instructions set forth in this clinical protocol.
- Be between 18 and 39 years of age (inclusive) at the time of screening.
- By self-report, habitually wear soft contact lenses in both eyes in a daily or daily disposable wear modality (i.e. not extended wear modality). Habitual wearer is defined as a minimum of 6 hours per day, for a minimum of 2 days per week during the past four weeks.
- Possess a wearable pair of spectacles that provide correction for distance vision.
- In both eyes, have refractive error suitable for correction with the toric contact lens powers available in this study:
- Sphere powers (DS) -1.50 through -4.00 in 0.25 steps
- Cylinder powers (DC) -0.75 and -1.25
- Axes (degrees) 170, 180, 10, 80, 90, 100
- Have best corrected monocular distance visual acuity of 20/30 or better in each eye.
Exclusion
- Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- Be currently pregnant or lactating.
- Be diabetic.
- Be currently using any ocular medications or have an ocular infection of any type.
- By self-report, have any ocular or systemic disease, allergies, infection, or use of medication that might contraindicate or interfere with contact lens wear, or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus \[HIV\]), autoimmune disease (e.g. rheumatoid arthritis, Sjögren's syndrome), or history of serious mental illness or seizures.
- Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 6 months.
- Be currently wearing monovision or multifocal contact lenses.
- Be currently wearing lenses in an extended wear modality.
- Have a history of strabismus or amblyopia.
- Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site.
- Have participated in a contact lens or lens care product clinical trial within 7 days prior to study enrollment.
Key Trial Info
Start Date :
May 9 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 9 2022
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT05344560
Start Date
May 9 2022
End Date
August 9 2022
Last Update
September 15 2023
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. James Weber & Associates, PA - City Square Blvd
Jacksonville, Florida, United States, 32218
2
Stam & Associates Eye Care
Jacksonville, Florida, United States, 32256
3
Sabal Eye Care
Longwood, Florida, United States, 32779
4
Maitland Vision Center - North Orlando Ave
Maitland, Florida, United States, 32751